Humacyte BLA for HAV gets Priority Review; PDUFA Aug 10, 2024; Q4 net loss $25.1M

Humacyte, Inc.

FDA accepted BLA for HAV with Priority Review in vascular trauma; PDUFA date August 10, 2024.
Raised ~$43.1M net from public offering in March 2024; additional $20M draw from Oberland.
Cash and equivalents $80.4M at Dec 31, 2023; net cash used $69.0M in 2023.
No revenue in Q4 2023; R&D expenses $20.2M (up from $15.0M), net loss $25.1M.
Full year 2023 net loss $110.8M vs $12.0M in 2022 due to non-cash remeasurement and higher expenses.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.